Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: J Orthop Res. 2020 Oct 6;39(7):1452–1462. doi: 10.1002/jor.24865

FIGURE 3.

FIGURE 3

(A) Typical immunofluorescence staining of FAPs treated the DMSO and TSA for 2 weeks (red-UCP-1, green-perilipin A, and blue-DAPI). Typical FAPs expressed UCP-1 were indicated with arrows. (B) Quantification of perilipin A(+) FAPs in TSA and DMSO-treated groups. (C) quantification of αSMA(+) FAPs in TSA and DMSO-treated groups. (D) RT-PCR showed that TSA treatment could increase the UCP1, PRDM16, Collagen I, and ACTA2 gene expression but decreased the adiponectin and PPARγ gene expression in FAPs. (E) Luciferase assay of UCP-1 driven luciferase reporter gene activity of UCP-1 reporter FAPs was significantly higher in the TSA-treated group compared with the DMSO-treated group (*p < .05). DAPI, 4′,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; FAPs, fibro/adipogenic progenitors; RT-PCR, real-time polymerase chain reaction; TSA, Trichostatin A; UCP-1, uncoupling protein-1; αSMA, alpha-smooth muscle actin